Implantica Expands Accessibility of RefluxStop™ with New Center in Spain

Implantica AG, a leading Med-Tech enterprise, has aimed to address the rising demand for gastroesophageal reflux disease (GERD) treatment by unveiling a new center dedicated to its RefluxStop™ device in Spain. Situated at the prestigious H. Univ. Marqués de Valdecilla in Cantabria, this center pioneers a new chapter in therapeutic options available for patients suffering from this chronic condition.

The demand for effective GERD treatments has seen a significant surge, with estimates indicating that around 15% of the adult population in Spain experiences symptoms related to GERD. Notably, for a percentage of these individuals, conventional medications fail to alleviate their painful symptoms. This creates an urgent necessity for viable surgical treatments that have historically been limited to select patients. Implantica’s innovative solution, RefluxStop™, offers a groundbreaking alternative, expanding the availability of surgical options to a broader patient demographic.

The First Procedures

At the center, leading surgeon Dra. Sonia Castanedo, along with her team members Dra. Marisol Trugeda and Surgery Manager Dr. Juan Carlos Rodríguez San Juan, recently conducted the first RefluxStop™ procedures. The efforts at H. Univ. Marqués de Valdecilla mark not only a historic moment for the institution, which has a rich history spanning nearly a century, but also for many patients in the region who have struggled with severe GERD.

Dra. Castanedo expressed her enthusiasm regarding the procedure: “The RefluxStop™ procedure offers a durable surgical treatment option for patients previously deemed unsuitable for conventional anti-reflux surgeries. The results documented in various studies have shown exceptional outcomes, and now I can personally attest to these successes,” she said, underscoring the significant impact this innovation could have on patients’ quality of life.

CEO Insights

Dr. Peter Forsell, CEO and founder of Implantica, shared his optimism regarding the swift uptake of the RefluxStop™ device by leading medical professionals, like Dra. Castanedo. He emphasized the historical lack of effective treatment alternatives available to GERD sufferers, noting that many have endured prolonged discomfort and dissatisfaction with their treatment options.

The RefluxStop™ device, distinct in its method, does not encircle the food passageway, thereby providing a solution that is far less invasive compared to traditional surgeries. This innovative mechanism restores the lower esophageal sphincter, maintaining its natural position, which is crucial for ensuring effective prevention against acid reflux.

Looking Ahead

With these advancements, Implantica is poised to significantly enhance the standard of care for GERD patients across Spain and beyond. As the new center begins operations, there is palpable hope for countless individuals seeking relief from a condition that has long hindered their daily lives.

The introduction of RefluxStop™ positions Implantica at the forefront of a potential paradigm shift in anti-reflux surgery, offering extensive clinical benefits without many of the side effects associated with older surgical methodologies. New developments in this area promise a brighter future for GERD treatment options and the overall well-being of affected patients throughout the region.

Conclusion

As this new center sets to work in Cantabria, it not only exemplifies Implantica’s commitment to innovation in medical technology but also highlights the critical need for effective solutions in managing GERD. With expectations running high, the RefluxStop™ center is set to transform lives and redefine the landscape of gastroesophageal reflux treatment in Spain and potentially in other regions facing similar medical challenges.